

# Pharmacy pipeline: Anticipated high-impact drug approvals and cost

## Autoimmune and inflammatory diseases

- 3Q 2026

**Brepocitinib**-Privant Therapeutics  
Oral once-daily dual TYK2/JAK1 inhibitor for dermatomyositis  
**Estimated WAC: \$250K–\$325K annually**
- 4Q 2026

**Cemdisiran**-Regeneron  
SC q3mo. RNAi therapeutic (complement pathway inhibitor) for generalized myasthenia gravis  
**Estimated WAC: \$450K–\$525K annually**
- 4Q 2026

**Gefurulumab**-AstraZeneca  
SC once-weekly C5 inhibitor for anti-AChR-positive generalized myasthenia gravis  
**Estimated WAC: \$350K–\$500K annually**
- 4Q 2026

**Imlifidase**-Hansa Biopharma  
One-time intravenous IgG-cleaving enzyme for desensitization of highly sensitized kidney transplant candidates with a positive crossmatch  
**Estimated WAC: \$300K–\$500K single dose**
- 4Q 2026

**Imsidolimab**-Vanda Pharmaceuticals  
IV induction followed by monthly SC IL-36 receptor inhibitor for generalized pustular psoriasis  
**Estimated WAC: \$275K–\$375K annually**
- 1Q 2027

**Lorecivivint**-Biosplice Therapeutics  
Intra-articular q6–12mo. CLK/DYRK inhibitor for knee OA  
**Estimated WAC: \$8K–\$15K annually**

- 2027

**Mivocabtagene autoleucel**-Kyverna Therapeutics  
IV one-time autologous CD19-directed CAR T-cell therapy for stiff person syndrome  
**Estimated WAC: \$525K–\$625K single dose**
- 4Q 2026

**Povetacicept**-Vertex  
SC once-monthly BAFF/APRIL inhibitor for IgA nephropathy  
**Estimated WAC: \$425K–\$500K annually**
- 1Q 2027

**Povorcitinib**-Incyte  
Oral once-daily selective JAK1 inhibitor for moderate-to-severe hidradenitis suppurativa  
**Estimated WAC: \$175K–\$250K annually**
- 4Q 2026

**Saroglitazar**-Zydus  
Oral PPAR α/γ agonist for primary biliary cholangitis  
**Estimated WAC: \$140K–\$165K annually**

## Cardiopulmonary diseases

- 4Q 2026

**Asundexian**-Bayer  
Oral once-daily factor XIa inhibitor for secondary prevention of ischemic stroke  
**Estimated WAC: \$8K–\$15K annually**
- 4Q 2026

**Molgramostim**-Savara  
Inhaled once-daily recombinant GM-CSF therapy for autoimmune pulmonary alveolar proteinosis  
**Estimated WAC: \$275K–\$350K annually**

## Endocrine and metabolic diseases

- 4Q 2026

**Cagrilintide-Semaglutide**-Novo Nordisk  
SC once-weekly amylin analogue + GLP-1 RA combination for chronic weight management  
**Estimated WAC: \$13K–\$16K annually**
- 1Q 2027

**Encaleret**-BridgeBio  
Oral twice-daily CaSR antagonist for autosomal dominant hypocalcemia type 1  
**Estimated WAC: \$325K–\$375K annually**
- 4Q 2026

**Insulin efsitora alfa**-Eli Lilly  
SC once-weekly basal insulin for type 1 and type 2 diabetes  
**Estimated WAC: \$3,500–\$5,000 annually**
- 4Q 2026

**Lorundrostat**-Mineralys Therapeutics  
Oral once-daily aldosterone synthase inhibitor for uncontrolled or resistant hypertension  
**Estimated WAC: \$9,500–\$11,500 annually**

- 3Q 2026

**Rebisufligene etisparvovec**-Ultragenyx  
IV one-time in-vivo gene therapy for MPS IIIA (Sanfilippo syndrome type A)  
**Estimated WAC: \$3.5M–\$4.25M single dose**
- 3Q 2026

**Tiratricol**-Egetis Therapeutics  
Oral once-daily thyroid hormone analogue for MCT8 deficiency (Allan-Herndon-Dudley syndrome)  
**Estimated WAC: \$450K–\$650K annually**

## Genetic disorders

- 3Q 2026

**Adrabetadex**-Mandos Health  
Intrathecal q2wk cyclodextrin therapy for infantile-onset Niemann-Pick disease type C  
**Estimated WAC: \$850K–\$1.2M annually**
- 3Q 2026

**Apitegromab**-Scholar Rock  
IV q4wk myostatin inhibitor for spinal muscular atrophy (SMA; adjunct therapy)  
**Estimated WAC: \$250K–\$400K annually**
- 3Q 2026

**Deramioceel**-Capricor Therapeutics  
IV q3mo allogeneic cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy  
**Estimated WAC: \$750K–\$900K annually**
- 3Q 2026

**Garetosmab**-Regeneron  
IV q4wk Activin A inhibitor for fibrodysplasia ossificans progressiva (FOP)  
**Estimated WAC: \$700K–\$850K annually**

- 2027

**Isaralgagene civaparvovec**-Sangamo Therapeutics  
IV one-time in-vivo gene therapy for Fabry disease  
**Estimated WAC: \$2M–\$2.8M single dose**
- 1H 2027

**Lonvoguran ziclumeran**-Intellia Therapeutics  
IV one-time in vivo gene-editing for prophylactic treatment of hereditary angioedema  
**Estimated WAC: \$2.2M–\$2.9M single dose**

- 3Q 2026

**Pariglasgene brecaparvovec**-Ultragenyx  
IV one-time in-vivo gene therapy for glycogen storage disease type Ia (GSDIa)  
**Estimated WAC: \$1.8M–\$2.5M single dose**
- 4Q 2026

**Ribitol**-BridgeBio  
Oral twice-daily supplementation therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)  
**Estimated WAC: \$550K–\$750K annually**
- 3Q 2026

**Zilganersen**-Ionis Pharmaceuticals  
Intrathecal q12wk antisense oligonucleotide for Alexander disease  
**Estimated WAC: \$600K–\$850K annually**

- 3Q 2026

**Zilurgisertib**-Mirum Pharmaceuticals  
Oral once-daily ALK2 inhibitor for fibrodysplasia ossificans progressiva (FOP)  
**Estimated WAC: \$600K–\$800K annually**

ANTICIPATED APPROVAL DATE:

- 3Q 2026
- 4Q 2026
- 1Q/1H 2027
- 2027

**Abbreviations:** AChR = acetylcholine receptor; ADC = antibody–drug conjugate; ALK = anaplastic lymphoma kinase; APRIL = a proliferation-inducing ligand; BAFF = B–cell activating factor; BCG = Bacillus Calmette–Guérin; BCMA = B–cell maturation antigen; BsA=bispecific antibody; BTK = Bruton tyrosine kinase; CAR = chimeric antigen receptor; CELMoD = cereblon E3 ligase modulator; CLK/DYRK = CDC-like kinase / dual-specificity tyrosine phosphorylation-regulated kinase; DEE = developmental and epileptic encephalopathy; EGFR = epidermal growth factor receptor; ER = estrogen receptor; FGFR2 = fibroblast growth factor receptor 2; FOP = fibrodysplasia ossificans progressiva; FVIIIa = factor VIIIa; GIST = gastrointestinal stromal tumor; GLP-1 RA = glucagon-like peptide-1 receptor agonist; GM-CSF = granulocyte-macrophage colony-stimulating factor; HER2 = human epidermal growth factor receptor 2; IgA = immunoglobulin A; IgG = immunoglobulin G; IL = interleukin; IM = intramuscular; IV = intravenous; JAK = Janus kinase; MCT8 = monocarboxylate transporter 8; mo = month; MPS = mucopolysaccharidosis; NMIBC = non–muscle-invasive bladder cancer; NSCLC = non-small cell lung cancer; OA = osteoarthritis; PCNSL = primary central nervous system lymphoma; PD-1 = programmed death-1; PPAR = peroxisome proliferator-activated receptor; q = every; RA = receptor agonist; RNAi = RNA interference; R/R = relapsed and/or refractory; SC = subcutaneous; SCN2A = sodium voltage-gated channel α-subunit 2; SCN8A = sodium voltage-gated channel α-subunit 8; SCLC = small cell lung cancer; SERD = selective estrogen receptor degrader; SMA = spinal muscular atrophy; TKI = tyrosine kinase inhibitor; TYK2 = tyrosine kinase 2; wk = week; VEGF = vascular endothelial growth factor

# Pharmacy pipeline: Anticipated high-impact drug approvals and cost

## Hematological diseases

● 3Q 2026  
**Denecimig (Mim8)**-Novo Nordisk  
SC (self-admin) once-weekly, q2wk, or once-monthly FVIIIa-mimetic BsA for prophylaxis of hemophilia A with or without inhibitors  
**Estimated WAC: \$700K–\$900K annually**

● 3Q 2026  
**Rusfertide**-Takeda  
SC once-weekly hepcidin mimetic for polycythemia vera  
**Estimated WAC: \$180K–\$260K annually**

## Infectious diseases

● 3Q 2026  
**Bepirovirsen**-GSK/Ionis Pharmaceuticals  
SC once-weekly antisense oligonucleotide administered for 24 weeks for chronic hepatitis B infection  
**Estimated WAC: \$50K–\$100K per 24-wk treatment course**

● 4Q 2026  
**Doruxapapogene ralaplasamid**-Inovio  
IM, 4-dose plasmid DNA-based therapeutic vaccine for recurrent respiratory papillomatosis (RRP)  
**Estimated WAC: \$425K–\$475K per treatment course**

## Neurology

● 3Q 2026  
**Relutrigine**-Praxis Precision Medicines  
Oral once-daily precision sodium channel inhibitor for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)  
**Estimated WAC: \$300K–\$400K annually**

● 3Q 2026  
**Tavapadon**-AbbVie  
Oral once-daily D1/D5 partial dopamine agonist for Parkinson's disease  
**Estimated WAC: \$20K–\$35K annually**

● 1Q 2027  
**Ulixacaltamide**-Praxis Precision Medicines  
Oral once-daily T-type calcium channel inhibitor for adults with essential tremor  
**Estimated WAC: \$18K–\$35K annually**

## Oncology

● 4Q 2026  
**Anitocabtagene autoleucel**-Arcellx/Kite (Gilead)  
IV one-time BCMA-directed autologous CAR T-cell therapy for R/R multiple myeloma  
**Estimated WAC: \$575K–\$625K single dose**

● 4Q 2026  
**Bezuclastinib**-Cogent Biosciences  
Oral once-daily TKI for treatment of GIST following imatinib therapy  
**Estimated WAC: \$300K–\$450K annually**

● 2027  
**Cretostimogene Grenadenorepvec**-CG Oncology  
Intravesical oncolytic immunotherapy (induction + maintenance) for BCG-unresponsive high-risk NMIBC  
**Estimated WAC: \$500K–\$625K annually**

● 3Q 2026  
**Daznelimgene lisbac**-OS Therapies  
IV q3wk Listeria-based therapeutic vaccine for recurrent, fully resected pulmonary metastatic osteosarcoma  
**Estimated WAC: \$200K–\$350K per 48-week treatment course**

● 4Q 2026  
**Giredestrant**-Genentech  
Oral once-daily SERD for ER-positive, HER2-negative early-stage breast cancer  
**Estimated WAC: \$175K–\$250K annually**

● 3Q 2026  
**Iberdomide**-Bristol-Myers Squibb  
Oral CELMoD administered with daratumumab and dexamethasone for R/R multiple myeloma  
**Estimated WAC: \$275K–\$350K annually**

● 4Q 2026  
**Ifinatamab deruxtecan**-Daiichi Sankyo/Merck  
IV q3wk B7-H3-directed antibody-drug conjugate (ADC) for previously treated extensive SCLC  
**Estimated WAC: \$300K–\$425K annually**

● 4Q 2026  
**Ivonescimab**-Summit Therapeutics  
IV q3wk PD-1/VEGF bispecific antibody for EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC following TKI therapy  
**Estimated WAC: \$240K–\$325K annually**

● 3Q 2026  
**Lirafugratinib**-Elevar Therapeutics  
Oral once-daily FGFR2 inhibitor for previously treated FGFR2 fusion/rearrangement-positive cholangiocarcinoma  
**Estimated WAC: \$400K–\$500K annually**

● 4Q 2026  
**Neladalkib**-Nuvalent  
Oral once-daily ALK-TKI for previously treated ALK-positive NSCLC  
**Estimated WAC: \$300K–\$350K annually**

● 4Q 2026  
**Tirabrutinib**-Deciphera  
Oral once-daily BTK inhibitor for R/R primary CNS lymphoma (PCNSL)  
**Estimated WAC: \$325K–\$400K annually**

● 4Q 2026  
**Zanzalintinib**-Exelixis  
Oral once-daily multikinase inhibitor for previously treated metastatic colorectal cancer  
**Estimated WAC: \$250K–\$350K annually**

● 3Q 2026  
**Zidesamtinib**-Nuvalent  
Oral once-daily ROS1-selective TKI for previously treated ROS1-positive NSCLC  
**Estimated WAC: \$400K–\$475K annually**

● 1Q 2027  
**Zipalertinib**-Taiho  
Oral twice-daily EGFR exon 20 insertion-targeted inhibitor for previously treated NSCLC  
**Estimated WAC: \$300K–\$375K annually**

ANTICIPATED APPROVAL DATE:

● 3Q 2026   ● 4Q 2026   ● 1Q/1H 2027   ● 2027

**Abbreviations:** AChR = acetylcholine receptor; ADC = antibody–drug conjugate; ALK = anaplastic lymphoma kinase; APRIL = a proliferation-inducing ligand; BAFF = B-cell activating factor; BCG = Bacillus Calmette-Guérin; BCMA = B-cell maturation antigen; BsA=bispecific antibody; BTK = Bruton tyrosine kinase; CAR = chimeric antigen receptor; CELMoD = cereblon E3 ligase modulator; CLK/DYRK = CDC-like kinase / dual-specificity tyrosine phosphorylation-regulated kinase; DEE = developmental and epileptic encephalopathy; EGFR = epidermal growth factor receptor; ER = estrogen receptor; FGFR2 = fibroblast growth factor receptor 2; FOP = fibrodysplasia ossificans progressiva; FVIIIa = factor VIIIa; GIST = gastrointestinal stromal tumor; GLP-1 RA = glucagon-like peptide-1 receptor agonist; GM-CSF = granulocyte-macrophage colony-stimulating factor; HER2 = human epidermal growth factor receptor 2; IgA = immunoglobulin A; IgG = immunoglobulin G; IL = interleukin; IM = intramuscular; IV = intravenous; JAK = Janus kinase; MCT8 = monocarboxylate transporter 8; mo = month; MPS = mucopolysaccharidosis; NMIBC = non–muscle-invasive bladder cancer; NSCLC = non-small cell lung cancer; OA = osteoarthritis; PCNSL = primary central nervous system lymphoma; PD-1 = programmed death-1; PPAR = peroxisome proliferator-activated receptor; q = every; RA = receptor agonist; RNAi = RNA interference; R/R = relapsed and/or refractory; SC = subcutaneous; SCN2A = sodium voltage-gated channel α-subunit 2; SCN8A = sodium voltage-gated channel α-subunit 8; SCLC = small cell lung cancer; SERD = selective estrogen receptor degrader; SMA = spinal muscular atrophy; TKI = tyrosine kinase inhibitor; TYK2 = tyrosine kinase 2; wk = week; VEGF = vascular endothelial growth factor